Salix Drug Patent Portfolio

Salix owns 7 orange book drugs protected by 65 US patents with Fenoglide having the least patent protection, holding only 4 patents. And Uceris with maximum patent protection, holding 16 patents. Given below is the list of Salix's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10011637 Ultra-pure agonists of guanylate cyclase C, method of making and using same 05 Jun, 2034
Active
US11142549 Ultra-pure agonists of guanylate cyclase C, method of making and using same 05 Jun, 2034
Active
US11834521 Ultra-pure agonists of guanylate cyclase C, method of making and using same 05 Jun, 2034
Active
US10016504 Compositions 10 Sep, 2033
Active
US10918723 Colon cleansing compositions and methods of use 10 Sep, 2033
Active
US8999313 Compositions 10 Sep, 2033
Active
US9326969 Compositions 10 Sep, 2033
Active
US9707297 Compositions 10 Sep, 2033
Active
US9616097 Formulations of guanylate cyclase C agonists and methods of use 20 Aug, 2032
Active
US9592252 Colonoscopy—preparation 11 Aug, 2032
Active
US10646512 Colonoscopy - preparation 25 Mar, 2032
Active
US10780112 Colonoscopy-preparation 09 Mar, 2032
Active
US10792306 Colonoscopy—preparation 09 Mar, 2032
Active
US11529368 Colonoscopy—preparation 09 Mar, 2032
Active
US11319346 Ultra-pure agonists of guanylate cyclase C, method of making and using same 01 Mar, 2032
Active
US9610321 Formulations of guanylate cyclase C agonists and methods of use 15 Sep, 2031
Active
US9919024 Formulations of guanylate cyclase C agonists and methods of use 15 Sep, 2031
Active
US9925231 Formulations of guanylate cyclase C agonists and methods of use 15 Sep, 2031
Active
US10307375 Controlled release and taste masking oral pharmaceutical composition 07 Sep, 2031
Active
US10660858 Controlled release and taste masking oral pharmaceutical composition 07 Sep, 2031
Active
US8895064 Controlled release and taste masking oral pharmaceutical composition 07 Sep, 2031
Active
US9132093 Controlled release and taste making oral pharmaceutical composition 07 Sep, 2031
Active
US9192581 Controlled release and taste masking oral pharmaceutical composition 07 Sep, 2031
Active
US10307417 Oral formulations and lipophilic salts of methylnaltrexone 10 Mar, 2031
Active
US10376505 Oral formulations and lipophilic salts of methylnaltrexone 10 Mar, 2031
Active
US8524276 Oral formulations and lipophilic salts of methylnaltrexone 10 Mar, 2031
Active
US8956651 Oral formulations and lipophilic salts of methylnal trexone 10 Mar, 2031
Active
US9314461 Oral formulations and lipophilic salts of methylnaltrexone 10 Mar, 2031
Active
US8865688 Compositions and methods for treatment of bowel diseases with granulated mesalamine 01 May, 2030
Active
US8420663 Peripheral opioid receptor antagonists and uses thereof 30 Sep, 2029
Active
US9180125 Peripheral opioid receptor antagonists and uses thereof 30 Sep, 2029
Active
US9492445 Peripheral opioid receptor antagonists and uses thereof 30 Sep, 2029
Active
US9724343 Peripheral opioid receptor antagonists and uses thereof 30 Sep, 2029
Active
US7041786 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis 30 Jan, 2028
Active
US7658944 Solid dosage form comprising a fibrate 09 Dec, 2024
Active
US8124125 Solid dosage form comprising a fibrate 01 Oct, 2024 Expired
US8481078 Solid dosage form comprising a fibrate 01 Oct, 2024 Expired
US9173847 Tablet comprising a fibrate 01 Oct, 2024 Expired
US7799897 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis 09 Jun, 2022 Expired
US8637451 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis 28 Mar, 2022 Expired
US10064878 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020 Expired
US10105374 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020 Expired
US10143698 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020 Expired
US7410651 Controlled release and taste masking oral pharmaceutical composition 09 Jun, 2020 Expired
US7431943 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020 Expired
US8293273 Controlled release and taste masking oral pharmaceutical composition 09 Jun, 2020 Expired
US8784888 Controlled release and taste masking oral pharmaceutical composition 09 Jun, 2020 Expired
US9320716 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020 Expired
US9532954 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020 Expired
USRE43799 Controlled release and taste masking oral pharmaceutical composition 09 Jun, 2020 Expired
US6551620 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018 Expired
US8337886 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018 Expired
US8496965 Pellet formulation for the treatment of the intenstinal tract 20 Apr, 2018 Expired
US8911778 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018 Expired
US8940328 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018 Expired
US8956647 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018 Expired
US6559158 Use of methylnaltrexone and related compounds to treat chronic opioid use side affects 03 Nov, 2017 Expired
US5840737 Omeprazole solution and method for using same 16 Jul, 2016 Expired
US6489346 Substituted benzimidazole dosage forms and method of using same 16 Jul, 2016 Expired
US6645988 Substituted benzimidazole dosage forms and method of using same 16 Jul, 2016 Expired
US6699885 Substituted benzimidazole dosage forms and methods of using same 16 Jul, 2016 Expired
US6780882 Substituted benzimidazole dosage forms and method of using same 16 Jul, 2016 Expired
US7399772 Substituted benzimidazole dosage forms and method of using same 16 Jul, 2016 Expired
USRE45198 Omeprazole solution and method for using same 15 Jul, 2016 Expired
US5914122 Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams 19 Dec, 2015 Expired


Given below is the list of recent legal activities going on the following drug patents of Salix.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed 10 Jun, 2024 US8293273 (Litigated)
Expire Patent 03 Jun, 2024 US9320716
Payment of Maintenance Fee, 4th Year, Large Entity 21 Mar, 2024 US10792306
Payment of Maintenance Fee, 4th Year, Large Entity 21 Feb, 2024 US10780112
Payment of Maintenance Fee, 12th Year, Large Entity 23 Jan, 2024 US8247425
Maintenance Fee Reminder Mailed 18 Dec, 2023 US9320716
Sequence Moved to Public Database 08 Dec, 2023 US11834521
Recordation of Patent Grant Mailed 05 Dec, 2023 US11834521
Patent Issue Date Used in PTA Calculation 05 Dec, 2023 US11834521
Email Notification 05 Dec, 2023 US11834521
Mail Patent eGrant Notification 05 Dec, 2023 US11834521
Recordation of Patent eGrant 05 Dec, 2023 US11834521
Patent eGrant Notification 05 Dec, 2023 US11834521
Email Notification 16 Nov, 2023 US11834521
Issue Notification Mailed 15 Nov, 2023 US11834521


Salix's Drug Patent Litigations

Salix's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 11, 2016, against patent number US8865688. The petitioner MycoNovo, Inc. et al., challenged the validity of this patent, with Salix Pharmaceuticals, Ltd. et al. as the respondent. Click below to track the latest information on how companies are challenging Salix's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7041786 March, 2022 Final Written Decision - Appealed
(08 Sep, 2023)
Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US7041786 October, 2022 Final Written Decision - Appealed
(08 Sep, 2023)
Bausch Health Ireland Limited et al. MSN Laboratories Private Ltd. et al.
US9610321 June, 2022 Institution Denied
(04 Jan, 2023)
Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9616097 June, 2022 Institution Denied
(04 Jan, 2023)
Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9919024 June, 2022 Institution Denied
(04 Jan, 2023)
Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9925231 June, 2022 Institution Denied
(04 Jan, 2023)
Bausch Health Ireland Limited et al. Mylan Pharmaceuticals Inc. et al.
US9320716 October, 2017 Terminated-Settled
(23 Apr, 2018)
Cosmo Technologies Limited Argentum Pharmaceuticals LLC
US9320716 March, 2017 Terminated-Settled
(17 Jan, 2018)
US8784888 March, 2017 Terminated-Settled
(20 Sep, 2017)
US8865688 December, 2015 FWD Entered
(19 May, 2017)
SALIX PHARMACEUTICALS, LTD. GeneriCo, LLC
US8865688 July, 2016 Terminated
(30 Nov, 2016)
Salix Pharmaceuticals, Ltd. et al. Mylan Pharmaceuticals Inc. et al.
US8865688 July, 2016 Terminated
(30 Nov, 2016)
Salix Pharmaceuticals, Ltd. et al. MycoNovo, Inc. et al.


Salix Drug Patents' Oppositions Filed in EPO

Salix drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 22, 2010, by Combimab, Inc.. This opposition was filed on patent number EP02721604A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP02721604A Apr, 2010 Hill, Christopher Michael Patent maintained as amended
EP02721604A Apr, 2010 CombiMab, Inc. Patent maintained as amended


Salix's Family Patents

Salix drugs have patent protection in a total of 51 countries. It's US patent count contributes only to 27.5% of its total global patent coverage. 11 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Salix Drug List

Given below is the complete list of Salix's drugs and the patents protecting them.


1. Apriso

Apriso is protected by 7 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8865688 Compositions and methods for treatment of bowel diseases with granulated mesalamine 01 May, 2030
(5 years from now)
Active
US6551620 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018
(6 years ago)
Expired
US8337886 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018
(6 years ago)
Expired
US8496965 Pellet formulation for the treatment of the intenstinal tract 20 Apr, 2018
(6 years ago)
Expired
US8911778 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018
(6 years ago)
Expired
US8940328 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018
(6 years ago)
Expired
US8956647 Pellet formulation for the treatment of the intestinal tract 20 Apr, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Apriso's drug page


2. Fenoglide

Fenoglide is protected by 4 patents, out of which 3 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7658944 Solid dosage form comprising a fibrate 09 Dec, 2024
(2 months from now)
Active
US8124125 Solid dosage form comprising a fibrate 01 Oct, 2024
(4 days ago)
Expired
US8481078 Solid dosage form comprising a fibrate 01 Oct, 2024
(4 days ago)
Expired
US9173847 Tablet comprising a fibrate 01 Oct, 2024
(4 days ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fenoglide's drug page


3. Plenvu

Plenvu is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10016504 Compositions 10 Sep, 2033
(8 years from now)
Active
US10918723 Colon cleansing compositions and methods of use 10 Sep, 2033
(8 years from now)
Active
US8999313 Compositions 10 Sep, 2033
(8 years from now)
Active
US9326969 Compositions 10 Sep, 2033
(8 years from now)
Active
US9707297 Compositions 10 Sep, 2033
(8 years from now)
Active
US9592252 Colonoscopy—preparation 11 Aug, 2032
(7 years from now)
Active
US10646512 Colonoscopy - preparation 25 Mar, 2032
(7 years from now)
Active
US10780112 Colonoscopy-preparation 09 Mar, 2032
(7 years from now)
Active
US10792306 Colonoscopy—preparation 09 Mar, 2032
(7 years from now)
Active
US11529368 Colonoscopy—preparation 09 Mar, 2032
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Plenvu's drug page


4. Relistor

Relistor is protected by 10 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10307417 Oral formulations and lipophilic salts of methylnaltrexone 10 Mar, 2031
(6 years from now)
Active
US10376505 Oral formulations and lipophilic salts of methylnaltrexone 10 Mar, 2031
(6 years from now)
Active
US8524276 Oral formulations and lipophilic salts of methylnaltrexone 10 Mar, 2031
(6 years from now)
Active
US8956651 Oral formulations and lipophilic salts of methylnal trexone 10 Mar, 2031
(6 years from now)
Active
US9314461 Oral formulations and lipophilic salts of methylnaltrexone 10 Mar, 2031
(6 years from now)
Active
US8420663 Peripheral opioid receptor antagonists and uses thereof 30 Sep, 2029
(4 years from now)
Active
US9180125 Peripheral opioid receptor antagonists and uses thereof 30 Sep, 2029
(4 years from now)
Active
US9492445 Peripheral opioid receptor antagonists and uses thereof 30 Sep, 2029
(4 years from now)
Active
US9724343 Peripheral opioid receptor antagonists and uses thereof 30 Sep, 2029
(4 years from now)
Active
US6559158 Use of methylnaltrexone and related compounds to treat chronic opioid use side affects 03 Nov, 2017
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Relistor's drug page


5. Trulance

Trulance is protected by 11 patents, out of which 2 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10011637 Ultra-pure agonists of guanylate cyclase C, method of making and using same 05 Jun, 2034
(9 years from now)
Active
US11142549 Ultra-pure agonists of guanylate cyclase C, method of making and using same 05 Jun, 2034
(9 years from now)
Active
US11834521 Ultra-pure agonists of guanylate cyclase C, method of making and using same 05 Jun, 2034
(9 years from now)
Active
US9616097 Formulations of guanylate cyclase C agonists and methods of use 20 Aug, 2032
(7 years from now)
Active
US11319346 Ultra-pure agonists of guanylate cyclase C, method of making and using same 01 Mar, 2032
(7 years from now)
Active
US9610321 Formulations of guanylate cyclase C agonists and methods of use 15 Sep, 2031
(6 years from now)
Active
US9919024 Formulations of guanylate cyclase C agonists and methods of use 15 Sep, 2031
(6 years from now)
Active
US9925231 Formulations of guanylate cyclase C agonists and methods of use 15 Sep, 2031
(6 years from now)
Active
US7041786 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis 30 Jan, 2028
(3 years from now)
Active
US7799897 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis 09 Jun, 2022
(2 years ago)
Expired
US8637451 Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis 28 Mar, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trulance's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Uceris

Uceris is protected by 16 patents, out of which 11 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10307375 Controlled release and taste masking oral pharmaceutical composition 07 Sep, 2031
(6 years from now)
Active
US10660858 Controlled release and taste masking oral pharmaceutical composition 07 Sep, 2031
(6 years from now)
Active
US8895064 Controlled release and taste masking oral pharmaceutical composition 07 Sep, 2031
(6 years from now)
Active
US9132093 Controlled release and taste making oral pharmaceutical composition 07 Sep, 2031
(6 years from now)
Active
US9192581 Controlled release and taste masking oral pharmaceutical composition 07 Sep, 2031
(6 years from now)
Active
US10064878 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020
(4 years ago)
Expired
US10105374 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020
(4 years ago)
Expired
US10143698 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020
(4 years ago)
Expired
US7410651 Controlled release and taste masking oral pharmaceutical composition 09 Jun, 2020
(4 years ago)
Expired
US7431943 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020
(4 years ago)
Expired
US8293273 Controlled release and taste masking oral pharmaceutical composition 09 Jun, 2020
(4 years ago)
Expired
US8784888 Controlled release and taste masking oral pharmaceutical composition 09 Jun, 2020
(4 years ago)
Expired
US9320716 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020
(4 years ago)
Expired
US9532954 Controlled release and taste masking oral pharmaceutical compositions 09 Jun, 2020
(4 years ago)
Expired
USRE43799 Controlled release and taste masking oral pharmaceutical composition 09 Jun, 2020
(4 years ago)
Expired
US5914122 Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams 19 Dec, 2015
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Uceris's drug page


7. Zegerid

Zegerid is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5840737 Omeprazole solution and method for using same 16 Jul, 2016
(8 years ago)
Expired
US6489346 Substituted benzimidazole dosage forms and method of using same 16 Jul, 2016
(8 years ago)
Expired
US6645988 Substituted benzimidazole dosage forms and method of using same 16 Jul, 2016
(8 years ago)
Expired
US6699885 Substituted benzimidazole dosage forms and methods of using same 16 Jul, 2016
(8 years ago)
Expired
US6780882 Substituted benzimidazole dosage forms and method of using same 16 Jul, 2016
(8 years ago)
Expired
US7399772 Substituted benzimidazole dosage forms and method of using same 16 Jul, 2016
(8 years ago)
Expired
USRE45198 Omeprazole solution and method for using same 15 Jul, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zegerid's drug page